OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Individualized pharmacotherapy requires identification of genetic variants predictive of treatment response. In OPRM1, Asn40Asp has been reported to be predictive of response to naltrexone treatment. Nevertheless, the in vitro function of the polymorphism remains elusive and over 300 OPRM1 sequence variants have been identified to date. Therefore we used a haplotype‐based approach to capture information of other genetic variants that might predict treatment response to naltrexone in the COMBINE Study. Methods: 5′ nuclease genotyping assays (TaqMan®) were applied for 10 SNPs. Five‐locus haplotypes in 2 OPRM1 haplotype blocks were assigned to Caucasian participants. The relationship of the haplotypes to medication reflected by “good clinical outcome” was analyzed in 306 Caucasians treated without Combined Behavioral Intervention and with either naltrexone or placebo. Results: A significant haplotype by medication interaction (p = 0.03) was found in OPRM1 block 1. Naltrexone‐treated alcoholics with haplotype AGCCC, the single haplotype carrying the Asp40 allele had the highest percent of good clinical outcome. When interaction of genotypes at each of the 5 loci comprising block 1 with medication was examined, only the Asn40/Asp40 and Asp40/Asp40 genotypes were found to significantly interact with naltrexone treatment. No haplotype by medication interaction was documented in OPRM1 block 2. Conclusions: Our haplotype‐based approach confirms that the single OPRM1 locus predictive of response to naltrexone treatment is Asn40Asp in exon 1. A substantial contribution of any other OPRM1 genetic variant to interindividual variations in response to naltrexone treatment (at least in terms of good clinical outcome) is not supported by our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Structure of Haplotype Blocks in the Human Genome
Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., et al. (2002) · Science · doi:10.1126/science.1069424 · Cited by 5,863
Naltrexone in the Treatment of Alcohol Dependence
Volpicelli, J. R. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820110040006 · Cited by 1,828
Exploring the opioid system by gene knockout
Kieffer, B. L., & Gavériaux-Ruff, C. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00008-4 · Cited by 620 · cited 1×
“Of the three receptor subtypes, the opioid receptor mu 1 (OPRM1) is thought to account for the most of the opioidergic effects (Kieffer and Gaveriaux-Ruff, 2002; Sora et al., 2001; Uhl et al., 1999).”
BackgroundNaltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Oslin, D. W., Berrettini, W., Kranzler, H. R., Pettinati, H., Gelernter, J., Volpicelli, J. R., & O'Brien, C. P. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300219 · Cited by 571 · cited 2×
“As mentioned above Asp40 has been shown to be predictive of response to naltrexone treatment in alcoholics by ourselves and at least one other group, (Anton et al., 2008; Oslin et al., 2003) and evidence has been provided for the in vitro and in vivo functionality of this missense variant.”
BackgroundSelf-citationAllelic Expression Imbalance of Human mu Opioid Receptor (OPRM1) Caused by Variant A118G
Zhang, Y., Wang, D., Johnson, A. D., Papp, A. C., & Sadée, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504942200 · Cited by 563 · cited 2×
“Additionally, in transfected CHO cells the Asp40 allele yielded 1.5-fold lower mRNA levels and more than 10-fold lower OPRM1 protein levels (Zhang et al., 2005).”
BackgroundInfluentialGenetic variation in human NPY expression affects stress response and emotion
Zhou, Z., Zhu, G., Hariri, A. R., Enoch, M.-A., Scott, D., Sinha, R., Virkkunen, M., Mash, D. C., Lipsky, R. H., Hu, X.-Z., et al. (2008) · Nature · doi:10.1038/nature06858 · Cited by 455
Self-citationAnton, R. F., Oroszi, G., O’Malley, S., Couper, D., Swift, R., Pettinati, H., & Goldman, D. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.2.135 · Cited by 451 · cited 6×
“…results can be found in a previous report (Anton et al., 2006) Specific details of those that participated in the genetic sub-study of the parent COMBINE Study can be found in a report focusing only on the relationship of the Asp40 variant to naltrexone treatment response (Anton et al., 2008).”
BackgroundResultSelf-citation
Cited by
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“A functional polymorphism, Asp40 allele, of the mu opioid receptor gene has been shown to predict naltrexone treatment response in alcohol-dependent individuals (Anton et al., 2008; Kim et al., 2009; Oroszi et al., 2009; Oslin et al., 2003) (Ib), but its impact may be moderated by other efficacious treatment or patien…”
BackgroundGarbutt, J. C., Kampov‐Polevoy, A. B., Gallop, R., Kalka‐Juhl, L., & Flannery, B. A. (2010) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2010.01273.x · Cited by 294
Heilig, M., Thorsell, A., Sommer, W. H., Hansson, A. C., Ramchandani, V. A., George, D. T., Hommer, D., & Barr, C. S. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.11.018 · Cited by 117
“In contrast, a haplotype based reanalysis of the COMBINE study found naltrexone response to be specifically attributable to 118G (Oroszi et al., 2009).”
BackgroundTreatment-refractory substance use disorder: focus on alcohol, opioids, and cocaine
Soyka, M., & Mutschler, J. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.11.003 · Cited by 49
Metadata
- Authors
- Oroszi, G., Anton, R. F., O’Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D.
- Venue
- Alcoholism: Clinical and Experimental Research
- Publisher
- Wiley
- Published
- 2009-02-19
- Volume
- 33
- Issue
- 3
- Pages
- 383-393
- ISSN
- 0145-6008 (ISSN-L)
- 1530-0277
- OpenAlex
- W2103303496
- Cited by
- 84
- References
- 8
- FWCI
- 5.45
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach. https://app.cochat.ai/papers/10.1111/j.1530-0277.2008.00846.x
- The paper
- Oroszi, G., Anton, R. F., O’Malley, S., Swift, R., Pettinati, H., Couper, D., Yuan, Q., & Goldman, D. (2009). OPRM1 Asn40Asp Predicts Response to Naltrexone Treatment: A Haplotype‐Based Approach. Alcoholism: Clinical and Experimental Research. https://doi.org/10.1111/j.1530-0277.2008.00846.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.